Reggiardo, Roman E. http://orcid.org/0000-0001-6309-249X
Maroli, Sreelakshmi Velandi
Peddu, Vikas http://orcid.org/0000-0002-0366-3956
Davidson, Andrew E.
Hill, Alexander http://orcid.org/0000-0001-8903-0297
LaMontagne, Erin
Aaraj, Yassmin Al
Jain, Miten http://orcid.org/0000-0002-4571-3982
Chan, Stephen Y.
Kim, Daniel H. http://orcid.org/0000-0003-0684-6245
Funding for this research was provided by:
American Cancer Society (RSG-22-099-01-CDP)
U.S. Department of Health & Human Services | National Institutes of Health (DK131504, HL122596, HL124021)
California Institute for Regenerative Medicine (EDUC4-12759)
Tobacco-Related Disease Research Program (T32DT4904)
American Heart Association (18EIA33900027)
Article History
Received: 22 August 2022
Accepted: 26 July 2023
First Online: 31 August 2023
Competing interests
: D.H.K. and R.E.R. are inventors on patent applications covering the methods and compositions to detect cancer using cell-free RNA submitted by the Regents of the University of California. D.H.K. and R.E.R. are founders and shareholders and D.H.K. is a board member of LincRNA Bio. S.Y.C. has served as a consultant to United Therapeutics and Acceleron Pharma. S.Y.C. has held research grants from Actelion, Bayer and Pfizer. S.Y.C. is a director, officer and shareholder of Synhale Therapeutics. S.Y.C. has submitted patent applications regarding metabolism in pulmonary hypertension.